CONTENTS

NOTE TO THE READER **1**

LIST OF PARTICIPANTS **3**

PREAMBLE **9**
A. GENERAL PRINCIPLES AND PROCEDURES 9
1. Background 9
2. Objective and scope 10
3. Selection of agents for review 11
4. Data for the *Monographs* 12
5. Meeting participants 12
6. Working procedures 13
B. SCIENTIFIC REVIEW AND EVALUATION 14
1. Exposure data 15
2. Studies of cancer in humans 16
3. Studies of cancer in experimental animals 20
4. Mechanistic and other relevant data 23
5. Summary 26
6. Evaluation and rationale 27
References 31

GENERAL REMARKS **33**

PERFLUOROOCTANOIC ACID **37**
1. Exposure Data 37
1.1 Identification of the agent 37
1.2 Production and use 39
1.3 Occurrence and exposure 41
1.4 Regulations and guidelines 49

2. Cancer in Humans . . . 49
2.1 Occupational exposure . . . 49
2.2 Community studies of high exposure . . . 54
2.3 Studies in the general population . . . 60
3. Cancer in Experimental Animals . . . 63
3.1 Rat . . . 63
3.2 Rainbow trout . . . 66
4. Mechanistic and Other Relevant Data . . . 68
4.1 Toxicokinetic data . . . 68
4.2 Genotoxicity and related effects . . . 77
4.3 Other mechanistic data relevant to carcinogenesis . . . 80
4.4 Organ toxicity . . . 90
4.5 Susceptible populations . . . 93
4.6 Mechanistic considerations . . . 94
5. Summary of Data Reported . . . 95
5.1 Exposure data . . . 95
5.2 Human carcinogenicity data . . . 96
5.3 Animal carcinogenicity data . . . 97
5.4 Mechanistic and other relevant data . . . 97
6. Evaluation . . . 97
6.1 Cancer in humans . . . 97
6.2 Cancer in experimental animals . . . 97
6.3 Overall evaluation . . . 98
References . . . 98

TETRAFLUOROETHYLENE . . . 111
1. Exposure Data . . . 111
1.1 Identification of the agent . . . 111
1.2 Production and use . . . 112
1.3 Occurrence and exposure . . . 113
1.4 Regulations and guidelines . . . 115
2. Cancer in Humans . . . 116
2.1 Cohort studies . . . 116
2.2 Case–control studies . . . 118
3. Cancer in Experimental Animals . . . 118
3.1 Mouse . . . 118
3.2 Rat . . . 121
4. Mechanistic and Other Relevant Data . . . 124
4.1 Toxicokinetic data . . . 124
4.2 Genotoxicity and related effects . . . 130
4.3 Biochemical and cellular effects . . . 131
4.4 Organ toxicity . . . 131
4.5 Susceptible populations . . . 133
4.6 Mechanistic considerations . . . 134

5. Summary of Data Reported 135
5.1 Exposure data 135
5.2 Human carcinogenicity data 135
5.3 Animal carcinogenicity data 136
5.4 Mechanistic and other relevant data 136
6. Evaluation 137
6.1 Cancer in Humans 137
6.2 Cancer in experimental animals 137
6.3 Overall evaluation 137
6.4 Rationale 137
References 137

1,2-DICHLOROPROPANE 141
1. Exposure Data 141
1.1 Identification of the agent 141
1.2 Production and use 142
1.3 Occurrence and exposure 143
1.4 Regulations and guidelines 145
2. Cancer in Humans 146
2.1 Cholangiocarcinoma among printing workers in Japan 146
2.2 Cholangiocarcinoma among printing workers outside Japan 152
3. Cancer in Experimental Animals 152
3.1 Mouse 152
3.2 Rat 155
4. Mechanistic and Other Relevant Data 156
4.1 Toxicokinetic data 156
4.2 Genetic and related effects 161
4.3 Biochemical and cellular effects 162
4.4 Organ toxicity 165
4.5 Susceptible populations 168
4.6 Mechanistic considerations 168
5. Summary of Data Reported 169
5.1 Exposure data 169
5.2 Human carcinogenicity data 169
5.3 Animal carcinogenicity data 170
5.4 Mechanistic and other relevant data 170
6. Evaluation 171
6.1 Cancer in humans 171
6.2 Cancer in experimental animals 171
6.3 Overall evaluation 171
References 171

DICHLOROMETHANE 177
1. Exposure Data 177
1.1 Identification of the agent 177
1.2 Production and use 179
1.3 Occurrence and exposure 181
1.4 Regulations and guidelines 184
2. Cancer in Humans 186
2.1 Introduction 186
2.2 Occupational cohort studies of workers exposed to dichloromethane 186
2.3 Case–control studies 192
2.4 Meta-analysis 206
3. Cancer in Experimental Animals 206
3.1 Mouse 206
3.2 Rat 212
3.3 Hamster 217
4. Mechanistic and Other Relevant Data 217
4.1 Toxicokinetic data 217
4.2 Genetic and related effects 225
4.3 Other mechanistic data relevant to carcinogenicity 231
4.4 Organ toxicity 233
4.5 Susceptible populations 236
4.6 Mechanistic considerations 237
5. Summary of Data Reported 240
5.1 Exposure data 240
5.2 Human carcinogenicity data 240
5.3 Animal carcinogenicity data 241
5.4 Mechanistic and other relevant data 242
6. Evaluation 242
6.1 Cancer in Humans 242
6.2 Cancer in experimental animals 243
6.3 Overall evaluation 243
6.4 Rationale 243
References 243

1,3-PROPANE SULTONE 257
1. Exposure Data 257
1.1 Identification of the agent 257
1.2 Production and use 258
1.3 Occurrence and exposure 259
1.4 Regulations and guidelines 260
2. Cancer in Humans 260
3. Cancer in Experimental Animals 260
3.1 Mouse 260
3.2 Rat 264

4. Mechanistic and Other Relevant Data 266
4.1 Toxicokinetic data 266
4.2 Genetic and related effects 266
4.3 Other effects relevant to carcinogenicity 269
4.4 Mechanistic considerations 269
5. Summary of Data Reported 270
5.1 Exposure data 270
5.2 Human carcinogenicity data 270
5.3 Animal carcinogenicity data 270
5.4 Mechanistic and other relevant data 270
6. Evaluation 271
6.1 Cancer in humans 271
6.2 Cancer in experimental animals 271
6.3 Overall evaluation 271
6.4 Rationale 271
References 271

LIST OF ABBREVIATIONS 275

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word 'risks' in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.